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Abstract
WHO 2016 classiﬁed glioblastomas into IDH-mutant and IDH-wildtype with the former having a better prognosis but there
was no study on IDH-mutant primary glioblastomas only, as previous series included secondary glioblastomas. We recruited
a series of 67 IDH-mutant primary glioblastomas/astrocytoma IV without a prior low-grade astrocytoma and examined them
using DNA-methylation proﬁling, targeted sequencing, RNA sequencing and TERT promoter sequencing, and correlated the
molecular ﬁndings with clinical parameters. The median OS of 39.4 months of 64 cases and PFS of 25.9 months of 57 cases
were better than the survival data of IDH-wildtype glioblastomas and IDH-mutant secondary glioblastomas retrieved from
datasets. The molecular features often seen in glioblastomas, such as EGFR ampliﬁcation, combined +7/−10, and TERT
promoter mutations were only observed in 6/53 (11.3%), 4/53 (7.5%), and 2/67 (3.0%) cases, respectively, and gene fusions
were found only in two cases. The main mechanism for telomere maintenance appeared to be alternative lengthening of
telomeres as ATRX mutation was found in 34/53 (64.2%) cases. In t-SNE analyses of DNA-methylation proﬁles, with an
exceptional of one case, a majority of our cases clustered to IDH-mutant high-grade astrocytoma subclass (40/53; 75.5%)
and the rest to IDH-mutant astrocytoma subclass (12/53; 22.6%). The latter was also enriched with G-CIMP high cases (12/
12; 100%). G-CIMP-high status and MGMT promoter methylation were independent good prognosticators for OS (p =
0.022 and p = 0.002, respectively) and TP53 mutation was an independent poor prognosticator (p = 0.013) when correlated
with other clinical parameters. Homozygous deletion of CDKN2A/B was not correlated with OS (p = 0.197) and PFS (p =
0.278). PDGFRA ampliﬁcation or mutation was found in 16/59 (27.1%) of cases and was correlated with G-CIMP-low
status (p = 0.010). Aside from the three well-known pathways of pathogenesis in glioblastomas, chromatin modifying and
mismatch repair pathways were common aberrations (88.7% and 20.8%, respectively), the former due to high frequency of
ATRX involvement. We conclude that IDH-mutant primary glioblastomas have better prognosis than secondary
glioblastomas and have major molecular differences from other commoner glioblastomas. G-CIMP subgroups, MGMT
promoter methylation, and TP53 mutation are useful prognostic adjuncts.

These authors contributed equally: Queenie Hoi-Wing Wong,
Kay Ka-Wai Li, Wei-Wei Wang

Introduction

Supplementary information The online version contains
supplementary material available at https://doi.org/10.1038/s41379021-00778-x.

The WHO 2016 Classiﬁcation of Tumours of the Central
Nervous System classiﬁed glioblastomas by the IDH status.
[1] IDH-wildtype glioblastomas make up the majority of the
tumours and have a poorer prognosis than IDH-mutant
glioblastomas. Secondary glioblastomas, which arise from a
previous low-grade astrocytoma, are regarded as mostly
IDH-mutant. Increasingly, IDH-mutant glioblastomas and
IDH-mutant low-grade astrocytomas have undergone scrutiny as only a small number of IDH-mutant glioblastomas
were evaluated for molecular pathology prior to the WHO
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2016 classiﬁcation [2]. Since then, there have been three
sizeable series of IDH-mutant glioblastomas including ours
[3–5]. Two studies [3, 4] have characterized the cohort
more extensively and shown that IDH-mutant glioblastomas
are a more heterogenous group for risk than hitherto
thought, with some having a poor prognosis, especially
those with CDKN2A/B homozygous deletion. A few studies
have also identiﬁed homozygous deletion of CDKN2A/B,
alone or in combination with other biomarkers, as a poor
prognosticator in IDH-mutant histologically low-grade diffuse astrocytomas [3, 6–10]. These studies prompted the
cIMPACT-NOW group to propose a replacement of the
term IDH-mutant glioblastoma with IDH-mutant astrocytoma, WHO Grade IV, and with CDKN2A/B homozygous deletion being a diagnostic hallmark irrespective of
whether other features of malignancy in astrocytomas,
such as necrosis or endothelial proliferation, are present or
not [11].
In a large series of 188 secondary glioblastomas, Hu
et al. showed that only 67% of them were IDH-mutant and
their prognosis was seemingly not dissimilar to that of IDHwildtype glioblastomas [12]. By the same token, Miller
et al. showed that once IDH-mutant low-grade gliomas
progressed, presumably with many becoming high-grade
gliomas, clinical progression was rapid [13]. Hence, it
seems that IDH-mutant glioblastomas or IDH-mutant
astrocytoma, Grade IV, can be separated clinically into
primary and secondary IDH-mutant glioblastomas. Hu et al.
extensively evaluated the mutational landscape of secondary glioblastomas and identiﬁed MET-exon14 skipping
(METex14) as a novel therapeutic target [12]. In this paper,
we collected a cohort of 67 IDH-mutant primary glioblastomas and evaluated its molecular landscape by DNAmethylation proﬁling, targeted sequencing, and RNA
sequencing, and in addition performed Sanger sequencing
for TERT promoter. We established G-CIMP status and
copy number alterations (CNA) for genes regarded as critical in the pathogenesis of glioblastomas. Finally, we correlated the molecular landscape with the clinical variables.
This is the largest single series of IDH-mutant glioblastoma
to our knowledge.

histological diagnosis of glioblastomas and with a clinical
history of <3 months [3] and there was no previous history
of a low grade astrocytoma. The cohort included 27 cases of
a previous study [4] but the secondary glioblastomas of that
series were excluded. Previous diagnostic workups of these
cases included Sanger sequencing for IDH1 and IDH2 and
they were shown to be IDH-mutant. Ethics approvals were
obtained from The Joint Chinese University of Hong
Kong–New Territories East Cluster Clinical Research Ethics Committee, and the Ethics Committees of Huashan
Hospital, Shanghai and The First Afﬁliated Hospital of
Zhengzhou University, Zhengzhou. The study was performed in accordance with the Declaration of Helsinki.
Hematoxylin-eosin stained sections were reviewed and the
diagnosis of glioblastoma was conﬁrmed by three pathologists (HKN, HC, WWW). The histological diagnoses were
as per WHO 2016 Classiﬁcation [1]. Data on patient
demographics and therapeutic treatment were retrieved from
institutional paper and electronic records. Survival data
were obtained from follow-up clinic visits and direct contact
with patients or close relatives via phone.

Materials and methods

Illumina inﬁnium methylationEPIC BeadChip array

Tumour samples

FFPE sections were sent to Shanghai, China (Sinotech
Genomics Co., Ltd), where the DNA was extracted, bisulﬁte modiﬁed and subjected to DNA-methylation proﬁling
by EPIC Illumina Inﬁnium Human (850k) Array following
the manufacture’s recommendation (Illumina). Unprocessed
IDAT ﬁles can be downloaded from http://www.acp.cuhk.
edu.hk/hkng. Background correction, global dye-bias normalization, and calculation of DNA-methylation level were

Tumour samples were retrieved from Prince of Wales
Hospital (Hong Kong, China), Hua Shan Hospital (Shanghai, China) and the First Afﬁliated Hospital of Zhengzhou
University (Zhengzhou, China) from 2008 onwards and
cases of primary IDH-mutant glioblastomas were selected.
They were from adult patients (>17 years old) with a

IDH1, IDH2, and TERT promoter mutation analysis
Only samples with IDH1 or IDH2 mutation were included
in this study. IDH1/2 and TERT promoter mutation was
evaluated by Sanger sequencing. In brief, crude cell lysate
was prepared from formalin-ﬁxed parafﬁn-embedded
(FFPE) sections accordingly [14]. DNA from the lysate was
ampliﬁed using forward primer (IDH1: 5′-CGGTCTTCAG
AGAAGCCATT-3′; IDH2 5′-AGCCCATCATCTGCAAA
AAC-3′; and, TERT 5′-GTCCTGCCCCTTCACCTT-3′),
reverse primer (IDH1: 5′-CACATTATTGCCAACATGA
C-3′; IDH2 5′-CTAGGCGAGGAGCTCCAGT-3′; and,
TERT 5′-CAGCGCTGCCTGAAACTC-3′), KAPA Robust
HotStart ReadyMix (Sigma)/KAPA HiFi HotStart ReadyMix (Sigma). Ampliﬁcation was conducted on a thermal
cycler according to the manufacturer’s recommendation.
PCR products were visualized on electrophoresis gel,
cleaned with a spin column-based PCR product puriﬁcation
kit (iNtRON Biotechnology) and sequenced with BigDye
Terminator Cycle Sequencing kit v1.1 (Life Technologies).
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parts of EPIC array preprocessing, and were performed
according to the previous publications [15, 16]. G-CIMP
status were determined using a random forest (RF) machine
learning algorithm as described in previous publications
[15, 16]. The most variable probes were used to generate
t-SNE plot according to Capper et al. study [17]. The t-SNE
(t-distributed stochastic neighbour embedding) plot was
generated with Rtsne R package. The raw IDAT ﬁles were
uploaded to DKFZ ‘Classiﬁer’ tool (https://www.molecula
rneuropathology.org) for supervised analysis using the RF
methylation class prediction algorithm [17]. MGMT promoter methylation status was computed by DKFZ
‘Classiﬁer’ tool.

Determination of copy number variations with EPIC
850k array
To determine copy number variations, probe-level signal
intensities were retrieved from the IDAT ﬁles and then
subjected to background correction and dye-bias normalization. Probes targeting the sex chromosomes, containing
single-nucleotide polymorphisms, or mapping to multiple
locations in the human genome were excluded to avoid
inaccurate assessment. Two sets of 50 control samples
derived from male and female donors were used for normalization [17]. Copy number variation analysis were performed using the ‘conumee’ R package in Bioconductor
(http://www.bioconductor.org/packages/release/bioc/html/
conumee.html). A log2 ratio +0.35 was used as a cutoff for
ampliﬁcation and a log2 ratio −0.415 was used for the
cutoff of homozygous losses [9].
GISTIC v2.0 analysis was conducted to identify signiﬁcantly recurrent copy number ampliﬁcation and deletions at arm-level and focal-level, deﬁned as affected
regions spanning <50% of a chromosome arm [18, 19].

Targeted sequencing
DNA was obtained from FFPE sections using GeneRead
DNA FFPE kit (Qiagen). The quality and quantity of
extracted DNA were assessed by QIAseq DNA QuantiMIZE Assay (Qiagen). Samples that passed quality control
were subjected to library preparation with a custom QIAseq
Targeted DNA Panel, covering the coding exons of 74
genes altered in gliomas and other CNS tumours. The DNA
libraries were then further assessed for quality and quantity.
Sequencing of libraries passing quality control was performed on MiSeq v3 (Illumina).
Paired-end reads were aligned to the hg19 (GRCh37)
build of the human reference genome with BWA-MEM
algorithm on GeneGlobe platform (Qiagen). Variants were
called using smCounter2 [20] and annotated using wANNOVAR [21]. Variants with the following criteria were

excluded: not passing quality ﬁlters, with variant allele
fractions of <5%, with variant allele counts of <5, or with
minor allele frequencies of >1% in overall human population
or East Asians or documented in public databases (1000
Genomes, ExAc, gnomAD exome and genome databases).

RNA sequencing
RNA was extracted from FFPE sections using RNeasy
FFPE kit (Qiagen). RNA passing quality control examination was subjected to cDNA synthesis and molecular
barcode-indexed ligation library preparation. Target capture
was done using TruSight RNA Pan-Cancer Panel (Illumina), which covered 1385 genes commonly involved in
cancer. Libraries were sequenced on MiSeq instrument
(Illumina).
Paired-end reads were aligned to human genome
assembly GRCh37 (hg19) and fusion genes were called
using the STAR aligner and STAR fusion caller [22, 23].
In-frame fusion genes with at least ﬁve junction reads were
further conﬁrmed by conventional RT-PCR.

Statistical analysis
Statistical analysis was performed on IBM SPSS software
v22. Overall survival (OS) was deﬁned as the period of time
between operation and death or the last follow-up.
Progression-free survival (PFS) was deﬁned as the time
between operation and recurrence revealed by neuroradiological ﬁnding. Chi-square or Fisher’s test was applied
to determine correlation between molecular alterations and
clinical parameters and between different molecular alterations. Survival curves were evaluated by the Kaplan–Meier
(KM) method, and log-rank test was done to compare survival distribution between groups. Multivariable analysis
was performed by Cox proportional hazards model.
P < 0.05 (two-sided) was considered statistically signiﬁcant.

Results
Samples and clinical data
A summary of clinical features of this study cohort is shown
in Table 1. A total of 67 IDH-mutant primary glioblastoma
samples were collected in this study. MRI studies showed
37/42 cases (88.1%) with enhancement on T1 but the
imaging records of 25 cases were no longer available for
review. For histological review, all cases showed variable
degrees of hypercellularity and cellular anaplasia. All
except 3 cases showed necrotic foci and 43 cases showed
microvascular proliferation, including the 3 cases without
necrosis. Male-to-female ratio was 1.6:1. The mean and

Q. H.-W. Wong et al.
Table 1 Clinical data summary.
Clinical features

All samples (n = 67)

Gender
Male

41 (61.2%)

Female

26 (38.8%)

Age at diagnosis (years old)
Mean ± SD

39.3 ± 12.2

Median

38.0

Tumour location: lobular involvement
Unilobular

52 (77.6%)

Multilobular

8 (11.9%)

Involvement of non-lobular areas

7 (10.4%)

Tumour location: lobe
Frontal lobe

48 (71.6%)

Temporal lobe

16 (23.9%)

Parietal lobe

4 (6.0%)

Occipital lobe

5 (7.5%)

Others

2 (3.0%)

Tumour enhancement pattern
Enhanced

37 (55.2%)

Not enhanced

5 (7.5%)

Unknown

25 (37.3%)

Operation
Gross total resection

56 (83.6%)

Subtotal resection

9 (13.4%)

Biopsy

1 (1.5%)

Unknown

1 (1.5%)

Adjuvant therapy
No adjuvant therapy

11 (16.4%)

Chemotherapy only

0 (0%)

Radiotherapy only

2 (3.0%)

Chemotherapy and radiotherapy

50 (74.6%)

Unknown

4 (6.0%)

Current status
Dead

40 (59.7%)

Alive

24 (35.8%)

Unknown

3 (4.5%)

Overall survival (months, Kaplan–Meier)
Median (95% CI)

39.4 (24.6–54.2)

2-year survival

64.1%

5-year survival

30.8%

A summary of clinical features of our cohort of IDH-mutant primary
glioblastomas.

median age at diagnosis were 39.3 years old and 38.0 years
old, respectively. Most patients received gross total resection (56/67; 83.6%). Most patients (n = 50; 74.6%) were
given both chemotherapy and radiotherapy. Radiotherapy
alone was given to 2 (3.0%) patients. Follow-up data for
overall survival (OS) and progression-free survival (PFS)

were available for 64 and 57 cases, respectively. The mean
and median follow-up periods were 58.9 months and
60.1 months, respectively. Median OS was 39.4 months,
with a 2-year survival of 64.1% and a 5-year survival of
30.8%. Median PFS was 25.9 months. Univariate Cox
regression was performed according to the clinical features,
including gender, age at diagnosis, tumour location,
operation, chemotherapy and radiotherapy (Supplementary
Table 1). Only being female was signiﬁcantly associated
with a better PFS (p = 0.011). Age had no correlation with
survival (OS: p = 0.297; PFS: p = 0.769).

IDH-mutant primary glioblastomas had a better
prognosis than IDH-wildtype glioblastomas and IDHmutant secondary glioblastomas
Our cohort of IDH-mutant primary glioblastomas showed a
median OS of 39.4 months and median PFS of 25.9 months.
This was a longer median OS than IDH-wildtype glioblastomas (13.6 months, p < 0.001, log-rank test; Fig. 1A)
as we could retrieve from established databases [24, 25] and
IDH-mutant secondary glioblastomas (18.8 months, p =
0.032, log-rank test; Fig. 1C) as we could retrieve from Hu
et al. [12]. Our cohort also had a longer median PFS than
IDH-wildtype glioblastomas (8.7 months, p < 0.001, logrank test; Fig. 1B) as in established databases [24, 25] and
IDH-mutant secondary glioblastomas (11.3 months, p =
0.002, log-rank test; Fig. 1D) as in Hu et al. [12].

Classiﬁcation of G-CIMP groups based on genomewide DNA-methylation proﬁling
We determined genome-wide DNA-methylation proﬁling in
53 IDH-mutant primary glioblastomas with sufﬁcient tissue
material for Illumina MethylationEPIC (850k) arrays. We
applied RF with a two-step process and assigned the samples into one of the two IDH-mutant methylation-based
glioma subgroups (G-CIMP-high and G-CIMP-low)
according to the previous publication [15]. The majority of
the samples belonged to G-CIMP-high group (36/53;
67.9%), and G-CIMP-low was present in 17/53 (32.1%) of
cases. As described below, G-CIMP-low tumours were
associated with PDGFRA ampliﬁcation (p = 0.005). The
correlations between G-CIMP-low and PDGFRA mutation,
and between G-CIMP-low and TP53 mutation were not
quite signiﬁcant (p = 0.060 and p = 0.056, respectively)
(also see the section Targeted Sequencing below).

DNA methylomes clustered with two main DNAmethylation classes
We then conducted an unsupervised clustering of our
samples using the reference cohorts and classes of the

Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas
Fig. 1 IDH-mutant primary
glioblastomas show better OS
and PFS than IDH-wildtype
glioblastomas and IDHmutant secondary
glioblastomas. A OS and B PFS
of IDH-mutant primary
glioblastomas in this study and
IDH-wildtype glioblastomas
from established databases
[24, 25]. C OS and D PFS
of IDH-mutant primary
glioblastomas in this
study and IDH-mutant
secondary glioblastomas
from literature [12].

German Cancer Research Centre (DKFZ) as per Capper
et al. [17], and also using the method of t-SNE dimensionality reduction as per that paper. As shown in Fig. 2,
with the exception of one case, all samples were clustered or
in close proximity to either the methylation class called IDH
glioma, subclass astrocytoma (A_IDH) or the methylation
class called IDH glioma, subclass high-grade astrocytoma
(A_IDH_HG). With the DBSCAN algorithm described
previously [26], the majority of our cohort were annotated
to IDH glioma, subclass high-grade astrocytoma (40/53;
75.5%), and 12/53 cases (22.6%) were annotated to IDH
glioma, subclass astrocytoma. There was one outlier clustered in proximity to the DKFZ classiﬁer glioblastoma, IDH
wildtype, subclass mesenchymal but Sanger sequencing and
targeted sequencing both conﬁrmed an IDH1-R132H
mutation for this case. A review of the histology conﬁrmed
regular features of glioblastomas and the H&E of this case
is provided in Supplementary Fig. 1. In view of the t-SNE

ﬁndings, we evaluated histologically all the cases designated to the methylation class IDH glioma, subclass astrocytoma (A_IDH) and conﬁrmed that the cases satisﬁed
WHO 2016 histological criteria for glioblastomas. Representative photomicrographs from these cases showing
necrotic foci are included in Supplementary Fig. 2. In spite
of the cohorts being IDH-mutant, no case was clustered
with 1p19q codeleted oligodendroglioma class.
Korshunov et al. studied 97 IDH-mutant glioblastomas,
which included both primary and secondary tumours, by
450k methylation array. They selected the 10 000 most
variably methylated CpG probes for unsupervised hierarchical clustering [3]. The results showed 84/97 cases
(86.6%) clustered to IDH-mutant high-grade glioma and
11/97 cases (11.3%) to IDH-mutant astrocytoma class. They
also had the odd outliers similar to us.
We then correlated the DNA-methylation classes to GCIMP status. We found a strong correlation between

Q. H.-W. Wong et al.

Fig. 2 Unsupervised clustering of reference cohort samples and 53
IDH-mutant primary glioblastomas using t-SNE dimensionality
reduction. The reference cohort of the DKFZ CNS tumour classiﬁer
includes 82 tumour and 9 non-tumour classes and they are shown as
circles of different colours. Except one case, all IDH-mutant primary

glioblastomas in this study (shown in red triangle or green diamond)
clustered close to the methylation class called IDH glioma, subclass
astrocytoma (A_IDH) or IDH glioma, subclass high-grade astrocytoma
(A_IDH_HG). Mutations of IDH in our samples were tested and
conﬁrmed by independent PCR and Sanger sequencing.

G-CIMP status and DNA-methylation class in IDH-mutant
glioblastomas (p = 0.017; Supplementary Table 2). GCIMP-low tumours (17/17) were clustered or near the IDH
glioma, subclass high-grade astrocytoma (A_IDH_HG). All
tumours clustered to IDH glioma, subclass astrocytoma
(A_IDH) were G-CIMP-high tumours. However, DNAmethylation classes were not associated with OS (p = 0.104)
and PFS (p = 0.181) in our cohort. Methylation classes were
also not associated with CDKN2A/B deletion, PDGFRA
ampliﬁcation, and TP53 mutation (see below). MGMT promoter methylation status can be derived directly from the
methylation proﬁling [17, 27]. Overall, 46/53 (86.8%) cases
were found to be MGMT promoter methylated. MGMT
promoter methylation was not associated with G-CIMP
status or methylation classes.

signiﬁcant ampliﬁcation at chromosomes 8q, 10p, and 12p
and signiﬁcant loss at chromosomes 3p, 4q, 9p, 10p, 10q,
11p, 13q, 14q, and 19q (Fig. 4A; q < 0.05). At focal-level,
we found recurrent ampliﬁcation regions on chromosomes
4q12, 8q24.21, 11q13.3, 11q14.1, 12p13.32, 12q14.1 and
13q33.3. Genes located in these regions include PDGFRA,
MYC, CCND1, CCND2, and CDK4 (Fig. 4B). We also
identiﬁed eight recurrent loss regions and they were on
chromosomes 4q35.1, 5q34, 6p21.32, 8p23.3, 9p21.3,
10q26.3, 11p15.4, and 13q14.2. Genes located in these
regions included the well-known CDKN2A and CDKN2B.
Chromosome 7 gain and chromosome 10 loss are molecular
hallmark of many glioblastomas, and cIMPACT-NOW 3
recommended that IDH-wildtype diffuse astrocytic glioma
with their combined whole chromosome loss would follow
an aggressive clinical course closely resembling that of an
IDH-wildtype glioblastoma despite their grade II or III
histology [29]. Thus, we in particular determined the frequency of +7/−10 in our cohort and found that only 4/53
cases (7.5%) had +7/−10.
At gene-level, we investigated genes with established
relevance in gliomas [9]. We employed the cutoff established in Shirahata et al. study to determine ampliﬁcation
and deletion. The results revealed that EGFR ampliﬁcation
which is frequently found in the regular glioblastomas was
infrequent in our cohort (6/53; 11.3%). Instead, in our
cohort, we detected ampliﬁcations of CDK4 (15/53; 28.3%),
CCND2 (12/53; 22.6%), ERBB2 (11/53; 20.8%), MYC (10/
53; 18.9%), MET (9/53, 17.0%) PDGFRA (8/53; 15.1%),

Copy number variation analysis showed signiﬁcant
differences from IDH-wildtype glioblastomas
A summary of the molecular ﬁndings in this cohort, together with copy number variations (CNVs) is depicted in
Fig. 3.
CNVs were found to be extremely useful derivatives of
DNA-methylation proﬁles in gliomas [9, 28]. We thus
determined CNVs from EPIC 850k array data according to
previous research [17]. We employed GISTIC analysis to
determine statistically signiﬁcant recurrent ampliﬁcations
and losses at arm-level and focal-level. At the arm-level, we
found that the IDH-mutant primary glioblastomas showed
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Fig. 3 Summary of the clinical and molecular characteristics of
IDH-mutant primary glioblastomas. The top black bar chart represents the OS of each sample in months. The coloured bar chart on the
right represents the frequency of tumours with the genetic and

genomic aberrations found in this study. The bottom black bar chart
indicates the number of mutations in each tumour identiﬁed by targeted sequencing. The central heatmap illustrates the molecular
alterations. Each column represents one sample.

and PIK3CA (2/53; 3.8%). PTEN deletion was identiﬁed in
6/53 cases (11.3%), and homozygous deletion of CDKN2A/
B was identiﬁed in 23/53 cases (43.4%) (Table 2). In our
cohort, we did not observe a difference in EGFR promoter

methylation between EGFR ampliﬁed and non-ampliﬁed
cases (p = 0.388).
When compared with IDH-wildtype glioblastomas in
TCGA databases [24, 25], our cohort had much fewer
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Fig. 4 Signiﬁcant CNVs identiﬁed by GISTIC 2.0. A Signiﬁcant
arm-level CNVs in IDH-mutant primary glioblastomas. Frequencies of
CNVs are shown on the x-axes, while the human chromosomes 1–22
are illustrated along the y-axis. Arms with signiﬁcant alterations (q <

0.05) are marked with an asterisk. Data on 13p, 14, 15p and 22p are
not shown and were not signiﬁcant. B Signiﬁcant focal-level CNVs in
IDH-mutant primary glioblastomas. Statistical signiﬁcance of CNVs is
indicated by false discovery rate Q values on the x-axes.

EGFR ampliﬁcations (11.3% vs. 43.2%). Our cohort however showed more ampliﬁcations of CCND2 (22.6% vs.
2.1%), ERBB2 (20.8% vs. 0%), MYC (18.9% vs. 1.2%), and

MET (17.0% vs. 4.0%). Similarly, some of the other genetic
alterations mentioned by the cIMPACT-NOW update 5 to
possibly be important in the pathogenesis of IDH-mutant
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Table 2 Survival analysis of
copy number alterations.

Gene or
chromosomal arm

Type of CNA

Frequency
(n = 53)

Percentage p value (OS) p value (PFS)

CDK4

Ampliﬁcation

15

28.30%

0.640

0.359

CCND2

Ampliﬁcation

12

22.60%

0.704

0.664

ERBB2

Ampliﬁcation

11

20.80%

0.738

0.601

MYC

Ampliﬁcation

10

18.90%

0.205

0.137

MET

Ampliﬁcation

9

17.00%

0.841

0.960

PDGFRA

Ampliﬁcation

8

15.10%

0.489

0.871

EGFR

Ampliﬁcation

6

11.30%

0.663

0.197

CDK6

Ampliﬁcation

5

9.40%

0.940

0.674

MDM4

Ampliﬁcation

5

9.40%

0.798

0.747

KRAS

Ampliﬁcation

4

7.50%

0.357

0.750

MYCN

Ampliﬁcation

4

7.50%

0.577

0.709

CCND1

Ampliﬁcation

3

5.70%

0.290

0.501

MDM2

Ampliﬁcation

2

3.80%

0.609

0.170

PIK3CA

Ampliﬁcation

2

3.80%

0.398

0.142

PPM1D

Ampliﬁcation

1

1.90%

0.270

0.271

FGFR1

Ampliﬁcation

0

0.00%

N/A

N/A

FGFR3

Ampliﬁcation

0

0.00%

N/A

N/A

CDKN2A/B

Homozygous
deletion

23

43.40%

0.197

0.278

CDKN2A

Homozygous
deletion

16

30.20%

0.290

0.138

CDKN2B

Homozygous
deletion

22

41.50%

0.077

0.097

RB1

Homozygous
deletion

9

17.00%

0.488

0.290

PTEN

Homozygous
deletion

6

11.30%

0.404

0.750

PIK3R1

Homozygous
deletion

3

5.70%

0.779

0.830

NF1

Homozygous
deletion

1

1.90%

0.585

N/A

14q

Homozygous
deletion

5

9.40%

0.822

0.816

N/A data not available.
Frequency of copy number alterations (CNAs) and their correlations with OS and PFS.

astrocytoma, Grade IV, were not very common in our IDHmutant primary glioblastomas: deletion of RB1 (9/53;
17.0%), ampliﬁcation of MYCN (4/53; 7.5%), and deletion
of PIK3R1 (3/53; 5.7%). No case displayed 1p19q
codeletion.
In G-CIMP-low tumours (n = 17), we identiﬁed signiﬁcant PDGFRA ampliﬁcation (p = 0.005). G-CIMP status
was not associated with other CNVs.
We also computed the frequency of CNVs in our cohort
by established method [30, 31]. We found that G-CIMP
high group had a signiﬁcantly lower frequency of CNVs
compared to the G-CIMP low group (p = 0.013; 4.43%
+/− 4.51% vs. 8.37% +/− 6.46%).

Gene fusion was very rare in IDH-mutant primary
glioblastomas
RNA sequencing was performed on 41 IDH-mutant primary
glioblastomas in our cohort with sufﬁcient materials. Surprisingly, only 4 intrachromosomal fusions were detected in
2/41 (4.9%) cases. The fusion genes were PTPRZ1-MET,
UBTD2-CSF1R, SARNP-MYL2 and LRP1-TRHDE. One
tumour carried three fusion genes. The PTPRZ1-MET
fusion gene was identiﬁed in 1/41 (2.0%) cases and the
same fusion was also found by Hu et al. in secondary
glioblastomas [12]. All four fusion genes were conﬁrmed by
RT-PCR and Sanger sequencing (Fig. 3; Supplementary

Q. H.-W. Wong et al.

Fig. 3). The fact that gene fusion was a rare event in our
cohort is different from what was found in glioblastomas in
general where gene fusions are abundant and fusion genes
are potential targets for therapy [32–34].

Targeted sequencing showed differences from IDHwildtype glioblastomas and IDH-mutant secondary
glioblastomas
Targeted next-generation sequencing was performed on
53 samples in our cohort using an in-house panel which
contains 74 genes relevant to the pathogenesis of brain
tumours (Supplementary Table 3). Overall, there are 7.98 ±
4.57 mutations/sample. All mutations are listed in Supplementary Table 4. Sanger sequencing was used to identify
TERT promoter mutations in 67 samples. The most signiﬁcant ﬁnding was the extremely low occurrence of TERT
promoter mutation (2/67; 3.0%). Both TERT promoter
mutations found were C228T. Other mutations that were,
interestingly, rarely found in our cohort were EGFR (2/53;
3.8%) MET (4/53; 7.5%), FGFR3 (5/53; 9.4%), and PTEN
(2/53; 3.8%). Another signiﬁcant ﬁnding was the high
incidence of ATRX (34/53; 64.2%) and TP53 (30/53,
56.6%) mutations (Table 3). Other recurrent mutations in
our cohort included KMT2D (18/53; 34.0%), FAT1 (14/53;
26.4%), POLE (12/53; 22.6%), KMT2C (11/53; 20.8%),
PTCH1 (11/53; 20.8%), PIK3CA (11/53; 20.8%), and
PDGFRA (10/53; 18.9%). DNA mismatch repair (MMR)
genes were mutated in a small proportion of cases (11
cases) including MSH6 (8/53; 15.1%), MSH2 (2/53; 3.8%),
PMS2 (2/53, 3.8/%), and MLH1 (1/53; 1.9%). All except
two cases showed only single MMR mutation. For these
two cases, one tumour had mutations of the MSH2 and
PMS2 while another had mutations of MSH2 and MSH6.
Germline DNA was not available for testing. No prior
chemotherapy was given as these were primary tumours
with ﬁrst presentations.
When compared with IDH-wildtype primary glioblastomas in the literature [35], our cohort of IDH-mutant
primary glioblastomas showed very few TERT promoter
mutations (3.0% vs. 80.4%). When compared with IDHwildtype glioblastomas in TCGA databases [24, 25], our
cohort also showed more mutations in ATRX (64.2% vs.
0%), TP53 (56.6% vs. 7.1%), KMT2D (34.0% vs. 0.4%),
FAT1 (26.4% vs. 0.4%), POLE (22.6% vs. 0.1%), PDGFRA
(18.9% vs. 1.8%), and MSH6 (15.1% vs. 0.4%). When
compared with IDH-mutant secondary glioblastomas in
literature [12], our samples had more mutations in PDGFRA
(18.9% vs. 5.2%) but fewer TP53 mutations (56.6% vs.
80%). Supplementary Table 5 summarizes the prevalence of
genetic and genomic alterations among IDH-mutant primary glioblastomas, IDH-wildtype glioblastomas, and IDHmutant secondary glioblastomas. We identiﬁed cases as

Table 3 Survival analysis of gene mutations.
Gene

Frequency
(n = 53)

Percentage p value (OS) p value (PFS)

ATRX

34

0.642

0.524

0.681

TP53

30

0.566

0.020

0.331

KMT2D

18

0.340

0.337

0.217

FAT1

14

0.264

0.296

0.871

POLE

12

0.226

0.395

0.28

KMT2C

11

0.208

0.793

0.439

PIK3CA

11

0.208

0.274

0.774

PTCH1

11

0.208

0.108

0.222

PDGFRA 10

0.189

0.279

0.278

KMT2B

9

0.170

0.123

0.072

NOTCH1 9

0.170

0.787

0.867

ROS1

9

0.170

0.094

N/A

SPTA1

9

0.170

0.741

0.148

MSH6

8

0.151

0.637

0.899

SETD2

8

0.151

0.364

0.422

NF1

7

0.132

0.100

0.907

CIC

6

0.113

0.643

0.614

FGFR3

5

0.094

0.295

0.802

KEL

5

0.094

0.797

0.884

N/A data not available.
Frequency of gene mutations and their correlations with OS and PFS.

suggestive of hypermutation when the number of mutations
was greater than the mean+2 S.D [36]. Three cases in this
cohort displayed a potential hypermutation state (3/53;
5.7%), and the frequency is lower than that in IDH-mutant
secondary glioblastomas (5.7% vs. 18.6%) [12]. Two of the
three potentially hypermutated cases incidentally also
showed MSH6 mutation as described above. Given the facts
that the size of our target panel was relatively small covering 74 genes and we lacked tissue materials, we could not
further conﬁrm hypermutation status. The two other genes
mentioned by cIMPACT-NOW update 5 [11] as having
possible pathogenetic signiﬁcance in IDH-mutant astrocytoma, Grade IV, were as follows: PIK3CA was mutated in
11/53 (20.8%) cases, and PIK3R1 was mutated in 4/53
(7.5%) cases.

Canonical pathways altered in IDH-mutant primary
glioblastomas
Three canonical pathways are well known to be aberrated in
glioblastomas, namely RTK/RAS/PI3K/AKT pathway,
TP53 pathway, and RB pathway. When we combined copy
number variation analysis with targeted sequencing results,
RTK/RAS/PI3K/AKT pathway was altered in 67.2% samples, with PDGFRA aberrations being the most common
(27%) (Fig. 5). TP53 pathway was altered in 59.7%
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Fig. 5 Frequency of pathway
alterations in IDH-mutant
primary glioblastomas,
including chromatin modiﬁers,
DNA mismatch repair genes,
RTK/RAS/PI3K/AKT pathway,
TP53 pathway, and RB
pathway.

samples, with TP53 aberrations being the most common
(53%). RB pathway was altered in 65.7% samples, with
CDKN2B deletion being the most common (42%). The
proportions of all three were lower than those observed in
IDH-wildtype glioblastomas as retrieved from TCGA:
RTK/RAS/PI3K/AKT (90%), TP53 (86%) and RB (79%)
pathways [24]. Two other pathways signiﬁcantly involved
in the pathogenesis of IDH-mutant primary glioblastomas
included chromatin modiﬁers (88.7%) and DNA mismatch
repair genes (20.8%). The former’s high level of involvement was due to the frequent mutations of ATRX as mentioned above. The alteration of signalling pathways in this

cohort of IDH-mutant primary glioblastomas is depicted in
Fig. 5.

Clinical correlations of molecular parameters
G-CIMP-high tumours showed a signiﬁcantly longer OS
than G-CIMP-low ones (median: 44.5 months vs.
24.7 months, p = 0.015, log-rank test; Fig. 6A). G-CIMPhigh tumours also displayed a trend towards longer PFS
compared to the G-CIMP-low tumours (Fig. 6B). MGMT
promoter methylation was correlated with a better OS (p =
0.001) and a better PFS (p = 0.042) (Fig. 6C, D).
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Fig. 6 G-CIMP subgroup,
MGMT promoter
methylation, and TP53
mutation are signiﬁcant
prognosticators in IDHmutant primary
glioblastomas. A OS and B PFS
of G-CIMP-high and G-CIMPlow IDH-mutant primary
glioblastomas. C OS and D PFS
of MGMT promoter methylation
in IDH-mutant primary
glioblastomas. E OS and F PFS
of TP53 mutation in IDH-mutant
primary glioblastomas.

TP53 mutation was correlated with a worse OS
(p = 0.020; Fig. 6E) but not PFS (p = 0.331; Fig. 6F). It is
the only major pathogenetic gene of which mutation or copy
number alteration was correlated with survival. Also,
PIK3R1 ampliﬁcation showed a trend toward poor overall
survival (p = 0.079).

In multivariate analysis, G-CIMP-high subgroup
(p = 0.022; Supplementary Table 6A) and MGMT promoter
methylation (p = 0.002; Supplementary Table 6B) were
both independent prognostic factors for better OS. TP53
mutation was an independent poor prognosticator for OS
(p = 0.013) (Supplementary Table 6C).
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Correlation with OS and PFS of other major genetic
aberrations, including copy number alterations and mutations, is depicted in Tables 2 and 3. Only genetic events
with signiﬁcant hits are included. Details can also be
referred to Fig. 3. None of the following genes or chromosomal arms which were discussed in previous publications as of potential pathogenetic signiﬁcance in IDHmutant gliomas was correlated with survival: ATRX, CDK4,
MET, MYCN, PIK3R1, or 14q [10, 11, 36]. Frequency of
CNVs was also not correlated with survival (OS: p = 0.645;
PFS: p = 0.598).
Among IDH-mutant glioblastomas including both primary and secondary glioblastomas, two studies including
ours concluded that CDKN2A was a marker for poor
prognosis [3, 4]. Both studies included secondary glioblastomas in the cohorts. However, in our cohort where
only IDH-mutant primary glioblastomas were studied,
homozygous deletion of CDKN2A interestingly was not
correlated with OS (p = 0.290) and PFS (p = 0.138)
(Table 2). CDKN2B homozygous deletion showed a trend
of poor OS (p = 0.077) and PFS (p = 0.097) (Table 2).
Deletion of CDKN2A/B was not correlated with OS (p =
0.197) or PFS (p = 0.278) (Supplementary Fig. 4A, B).

Discussion
This study showed that IDH-mutant primary glioblastomas
had a better survival than the more common IDH-wildtype
glioblastomas as retrieved from the TGCA datasets [24, 25].
While this is as expected, as a matter of fact, the number of
IDH-mutant glioblastomas with survival data as examined
by Yan et al. in their seminal paper was only 14 [2]. Since
then there have been only been three sizeable series of IDHmutant glioblastomas [3–5]. Two of these series [3, 4]
contained both primary and secondary IDH-mutant glioblastomas and the situation is uncertain for the other [5].
And the former two conducted more extensive characterization than the latter. Our present cohort, while overlapping
with one of the previous series [4], contained only primary
tumours with the secondary tumours removed. Additional
new cases of IDH-mutant primary glioblastomas have been
added to the series in our present study. Secondary glioblastomas were already extensively investigated by Hu et al.
for molecular landscape [12] and they found MET-exon
14 skipping (METex14) as a potential therapeutic target for
secondary glioblastomas. Interestingly, our cohort showed
for the ﬁrst time that primary glioblastomas, when they
were of the IDH-mutant genotype, had a better prognosis
than IDH-mutant secondary glioblastomas as documented
by Hu et al. This corroborates the clinical ﬁndings that IDHmutant diffuse astrocytomas, once they progress presumably with many becoming high-grade gliomas, will

become aggressive [13]. This may be due to the fact that
most Grades 2–3 astrocytomas would have been treated
with chemoradiotherapy before progressing to glioblastomas and studies have demonstrated that IDH-mutant
cells can undergo clonally expansion to obtain growth
advantage and post-treatment mutant gliomas responded to
PD-1 blockade poorly [37, 38]. Our study is the largest
single series of IDH-mutant glioblastoma to our knowledge.
In this study, although the prognosis of IDH-mutant
primary glioblastomas was relatively good compared with
the regular glioblastomas, with a median OS of 39.4 months
and a 5-year survival of only 30.8%, it was still not a lowgrade tumour. The prognosis we showed in this cohort was
still much worse than the prognosis of low-grade IDHmutant astrocytomas as recorded in the literature [9, 10, 30].
However, it is possible that some IDH-mutant primary
glioblastomas may be molecularly akin to IDH-mutant
astrocytoma and similar clustering was also observed by
Korshunov et al. [3]. It is hard to be certain whether intratumoral heterogeneity and regional variation of molecular
changes among tumour clones have affected the results of
ours and Korshunov’s [3]. But our genome-wide DNAmethylation analysis also showed that many G-CIMP-high
cases were clustered to the IDH-mutant astrocytoma
methylation class. Furthermore, G-CIMP-high tumours
were associated with a favourable outcome and G-CIMP
subgroups and MGMT promoter methylation were independent favourable prognosticators for overall survival.
Surprisingly, fusion genes were identiﬁed in only two
cases in this study. This is in contrast to the common fusion
events involving genes like EGFR, FGFR3, MET, and
NTRK1/2/3 in glioblastomas [24, 32, 33]. IDH-mutant primary glioblastomas showed extensive differences from
IDH-wildtype glioblastomas. The most signiﬁcant ﬁndings
were that the key molecular markers for the diagnosis of the
common glioblastoma, namely EGFR ampliﬁcation or
mutation, 10q loss or PTEN mutation, and TERT promoter
mutation, were rare in IDH-mutant primary glioblastomas
[24, 25, 35]. Like us, Korshunov et al. also found only a
very small number of cases with TERT promoter mutations
in their series [3]. Telomere maintenance seemed to be done
via the alternative lengthening of telomeres (ALT)
mechanism with a high percentage of ATRX mutation
(64.2%) [39–41]. ATRX mutations are known to be associated with IDH-mutant gliomas [42, 43]. Very signiﬁcantly, EGFR ampliﬁcation, combined 7+/10− and
TERT promoter mutation [11, 44, 45] were only found in 6/
53 (11.3%), 4/53 (7.5%), and 2/67 (3.0%) cases, respectively, in our cohort.
The three well-known pathways involved in glioblastoma pathogenesis, namely RTK/RAS/PI3K/AKT,
TP53, and RB pathways, were involved to a lesser extent in
our cohort when compared with TCGA [25] while
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Fig. 7 Summary of clinical ﬁndings in this study. IDH-mutant
glioma can be classiﬁed as glioblastoma or Grade IV astrocytoma with
the following criteria. The prognosis of IDH-mutant glioblastomas can

be stratiﬁed by clinical history and molecular testing of MGMT promoter methylation, G-CIMP subgroup, and TP53 mutation.

mismatch repair genes and chromatin modifying pathways
were signiﬁcantly involved. The latter was involved in a
majority of cases because of the high incidence of ATRX
mutation, suggesting that IDH-mutant primary glioblastomas make use of the ALT (alternative lengthening for
telomeres) mechanism for telomere maintenance instead of
TERT promoter mutation [38, 40]. For the mismatch repair
genes, their mutations did not seem to lead onto hypermutations as can be seen in other gliomas with mutations of
these genes [38, 46].
cIMPACT-NOW update 5 proposed CDKN2A/B deletion to be a diagnostic marker for IDH-mutant astrocytoma
IV/IDH-mutant glioblastoma [11] and two studies examining IDH-mutant glioblastomas, inclusive of both primary
and secondary tumours, concluded CDKN2A deletion as a
prognosticator for this group of tumours [3, 4]. Our ﬁndings
were consistent with the cIMPACT-NOW’s proposal to use
CDKN2A/B deletion as a diagnostic criteria for an IDHmutant astrocytoma being Grade IV, as this was found in
43.4% of this series. G-CIMP subgroup and MGMT promoter methylation were independent good prognosticators
and TP53 mutation was an independent poor prognosticator. MGMT promoter methylation has been an
established prognosticator for glioblastoma [47, 48] and
Ceccarelli et al. have shown the utility of G-CIMP status in
the prognostication of IDH-mutant gliomas though their
series consisted mostly of lower grade IDH-mutant gliomas
[15]. Our ﬁndings showed that in IDH-mutant primary

glioblastoma itself, prognostication should be based on GCIMP subgroup, MGMT promoter methylation, and TP53
mutation instead of relying on CDKN2A homozygous
deletion alone. Clinical management of IDH-mutant primary glioblastomas which are G-CIMP-low or MGMT
promoter unmethylated or TP53 mutated should take into
consideration of the poorer prognosis of these tumours in
spite of their mutant IDH genotype. Figure 7 depicts the
prognostic signiﬁcance of molecular features identiﬁed in
this study.
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